[Previous][Table of Contents][Next]
Only confirmed cases of disease should be notified.
Routine case-by-case notification to the federal level
Detection of anti-hepatitis C antibodies (
anti-HCV) (positive anti-HCV tests should be
confirmed by a second manufacturer’s EIA,
immunoblot or NAT for HCV RNA).
OR
Detection of hepatitis C virus RNA
Anti-HCV testing should not be performed in infants < 18 months of age as the anti-HCV may represent passive maternal antibody. As most infections occur at the time of childbirth, if testing for HCV RNA is considered, it should be delayed beyond 4 to 12 weeks to avoid false-negative HCV RNA test results. Cord blood should not be used because of potential cross-contamination with maternal antibody.
The HCV serologic window period is approximately 5-10 weeks, and it is estimated that 30% of acute infections may be missed if anti-HCV is the only marker of infection used during this period. HCV-RNA is detectable within two to three weeks of infection and, in the context of clinical illness, can identify acute HCV infection even in the absence of anti-HCV.
If HCV-RNA is used solely to confirm active infection, a repeat test is recommended.
Confirmation of acute infection requires a documented seroconversion, i.e. in a previously anti-HCV seronegative individual.
Approximately 25% (range 15% to 45%) of HCV infections will resolve spontaneously. These individuals will typically demonstrate anti-HCV without detectable HCV RNA (using a test with a lower limit of detection of 10-50 IU/mL)
Immunocompromised individuals may not develop anti-HCV (e.g. HIV infection with CD4 counts < 50). These individuals may need to undergo HCV RNA testing.
Positive anti-HCV tests should be confirmed by a second manufacturer’s EIA, immunoblot or NAT for HCV RNA.
Acute clinical illness is characterized by a discrete onset of symptoms and jaundice or elevated serum aminotransferase levels. Chronic infections may present with disease flares with similar symptoms and signs.
B17.1, B18.2
070.70, 070.71, 070.41, 070.44, 070.51, 070.54
None
Case definitions for diseases under national surveillance. CCDR 2000;26(S3). Retrieved May 2008, from http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/00vol26/26s3/index.html
September 2008
[Previous][Table of Contents][Next]
To share this page just click on the social network icon of your choice.